Clinical decision making in cancer care: a review of current and future roles of patient age by Tranvåg, Eirik Joakim et al.
RESEARCH ARTICLE Open Access
Clinical decision making in cancer care:
a review of current and future roles of
patient age
Eirik Joakim Tranvåg1,2*, Ole Frithjof Norheim1,2 and Trygve Ottersen3,4
Abstract
Background: Patient age is among the most controversial patient characteristics in clinical decision making. In
personalized cancer medicine it is important to understand how individual characteristics do affect practice and
how to appropriately incorporate such factors into decision making. Some argue that using age in decision making
is unethical, and how patient age should guide cancer care is unsettled. This article provides an overview of the use
of age in clinical decision making and discusses how age can be relevant in the context of personalized medicine.
Methods: We conducted a scoping review, searching Pubmed for English references published between 1985 and
May 2017. References concerning cancer, with patients above the age of 18 and that discussed age in relation to
diagnostic or treatment decisions were included. References that were non-medical or concerning patients below
the age of 18, and references that were case reports, ongoing studies or opinion pieces were excluded. Additional
references were collected through snowballing and from selected reports, guidelines and articles.
Results: Three hundred and forty-seven relevant references were identified. Patient age can have many and diverse
roles in clinical decision making: Contextual roles linked to access (age influences how fast patients are referred to
specialized care) and incidence (association between increasing age and increasing incidence rates for cancer);
patient-relevant roles linked to physiology (age-related changes in drug metabolism) and comorbidity (association
between increasing age and increasing number of comorbidities); and roles related to interventions, such as
treatment (older patients receive substandard care) and outcome (survival varies by age).
Conclusions: Patient age is integrated into cancer care decision making in a range of ways that makes it difficult to
claim age-neutrality. Acknowledging this and being more transparent about the use of age in decision making are
likely to promote better clinical decisions, irrespective of one’s normative viewpoint. This overview also provides a
starting point for future discussions on the appropriate role of age in cancer care decision making, which we see as
crucial for harnessing the full potential of personalized medicine.
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Background
Among the many patient characteristics that can affect
decision making, patient age is both widely used and
heavily discussed. Using age appears intuitive in many
settings, but exactly how it should guide clinical
decisions is unsettled. Incorporating patient age into
decision making is by some seen as unethical and dis-
criminatory. Surveys demonstrate that oncologists use
patient age when recommending treatment, even when a
large majority at the same time state that they are
against such use [1, 2]. Among the public, empirical
studies demonstrate no consensus on the appropriate
role of age when allocating resources [3, 4], although a
recent systematic review demonstrated that the public
generally favors the young over the elderly when having
to give priority to one of the groups [5]. Theoretical
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arguments are used both for [6, 7] and against [8] the
relevance of age as a criteria when allocating resources.
To our knowledge there exists no overview of the role
of patient age in clinical decision making in cancer care.
Most studies describe age in association with some pre-
defined outcome, like treatment selection, survival or
shared decision making. A broader examination of how
age can influence decision making will benefit both clin-
ical practice and ethical discussion, irrespective of one’s
view on the proper role of age. If the use of age is con-
sidered unacceptable, it is imperative to identify all the
ways age actually makes an influence. If every use of age
in decision making is discriminatory, every such use of
age should be mapped. Equally, if age in some ways can
be accepted as guidance for decision making, it is im-
portant to know how and to what extent.
With the progress of personalized medicine, attention
to individual characteristics will be stronger. In oncology
practice it will be increasingly important to understand
how patient characteristics affect cancer biology, treat-
ment efficacy, and tolerance [9], as will appropriately in-
corporating such factors into decision making.
The aim of this study is to provide an overview of the
many different ways patient age may guide clinical deci-
sions in oncology. We will identify and discuss associa-
tions between age and clinical decisions, and explore
how age may be relevant for decision making in the
context of personalized medicine.
Methods
We conducted a scoping review [10] that identified lit-
erature covering the use of patient age in cancer diag-
nostic and treatment decisions. A scoping review is to
some extent similar to a systematic review, but there are
also several fundamental differences. Systematic reviews
address well-defined research questions that can be an-
swered by established methods, and use in-depth assess-
ments of the quality of included studies. Scoping reviews
address broader research questions, and can be used to
map key concepts of research areas, identify gaps in
existing knowledge or merely identify relevant literature
on a topic. A scooping review is therefore appropriate to
map the many ways patient age may guide clinical
decisions in oncology. Scoping reviews do not always
assess the quality of included studies, and the synthesis
of evidence is typically not quantitative, as it is in
systematic reviews [10–12].
We pre-defined our search objective, inclusion criteria
and method according to scoping review standards [12].
We searched Pubmed January 21 2016 by combining
search terms related to cancer, age and decision making
as follows: “(cancer[title] OR “neoplasms”[MeSH
Terms]) AND (“age”[Title] OR “age factors”[Mesh])
AND (“decision making”[MeSH Terms] OR decision
making[Title/abstract])”, and limited to references pub-
lished after 1985. References concerning cancer, with pa-
tients above the age of 18 and that discussed age in
relation to diagnostic or treatment decisions were in-
cluded. To include newly published research, we did an
updated search May 15 2017. We collected additional
references through snowballing and from selected re-
ports, guidelines and previously identified articles.
Duplicates were removed and missing abstracts re-
trieved. Then the abstracts were screened, and refer-
ences that fulfilled our aim were included. We applied
the following exclusion criteria: age under 18 (as we ac-
knowledge that pediatric oncology is a distinct field of
medicine), not medically oriented (as the decisions are
not taken by physicians), comments and editorials (as
they are opinion pieces) and case reports, preliminary
findings and ongoing studies (as they are incomplete).
Due to the large number of references identified we do
not cite them all. Details on all identified articles, includ-
ing publication year, country, type and keywords on con-
tent were gathered in a table and are available in the
Additional file 1: Appendix.
Using the chartered details from all references, we an-
alyzed the content of each reference and identified a
main topic. We then organized the references based on
the topic under three main categories: Context, Patient,
and Intervention. This grouping was done after the
search, partly in order to organize our findings, and
partly to structure and present it in a clinically relevant
and informative manner. If a reference fit more than one
category, the one best describing the overall aim of the
reference was selected. A narrative summary with se-
lected examples from our search describes findings and
how they relate to our objectives.
Results
Eight hundred sixty three references were identified (see
Fig. 1), including both original research and review arti-
cles. After removing duplicates, 861 abstracts were
screened using the pre-defined criteria. Of the 347 refer-
ences identified as relevant, 61 were categorized in the
Context group, 71 in the Patient group and 215 in the
Intervention group.
Our main finding is that age is associated with and
partly influences clinical decisions in ways that are both
avoidable, as for access to care (age influences how
quickly patients are referred to specialized care) or
participation in research (older patients are often under-
represented in clinical trials), and unavoidable, as for in-
cidence (strong association between increasing age and
increasing incidence rates for cancer) or comorbidity
(association between increasing age and increasing num-
ber of comorbidities) or treatment outcomes (decreased
survival for older patients). In total these publications
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show that patient age can be used – directly or indirectly
and consciously or unconsciously – to guide decisions
(see Table 1).
Context
We identified 61 relevant articles associating patient age
with factors relevant for the context of a clinical deci-
sion. Patient age can influence access to diagnostics and
treatment, incidence of cancer, clinical trials and evi-
dence, screening and guideline content.
Access to diagnostics and treatment can be heavily in-
fluenced by patient age. Young and old-aged patients
recognize fewer cancer symptoms, compared to those
aged between 55 and 74 years [13]. And according to
the same study by Niksic et al., the number of barriers
to present symptoms to a physician decreases with
Fig. 1 The flow of information through our scoping review
Table 1 Summary of main findings, with examples
Category Factor Example
Context Access Age influences how fast patients are referred to specialized care
Incidence Strong association between increasing age and increasing incidence rates for cancer
Research Participants in clinical trials often younger than actual disease population
Screening Strict age cut-offs for inclusion in public screening programs
Guidelines Clinical guidelines use age thresholds when recommending treatment
Patient Physiology Age-related declines in CYP enzymes responsible for hepatic drug metabolism
Tumor biology Proportion of ER and HER2 status in breast cancer varies between age groups
Comorbidity Association between increasing age and increasing number of comorbidities
Receptivity Physicians’ recommendations are more influential for older patients
Intervention Quality Older patients tend to receive substandard treatment
Prediction Risk prediction tools use age for estimations
Treatment outcome High age is often a predictor of decreased survival
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increasing age. When examined, age can influence how
fast the patient is referred to further investigation and/or
specialist care [14]. Older patients with advanced can-
cers are less likely to be referred to oncology teams [15]
compared to younger patients. And when in specialized
care, age can influence the decision to refer to certain
types of treatment [16].
There is a well-established link between increasing age
and increasing incidence rates for cancer worldwide
[17]. In Norway, more than 90% of cancers in men and
85% in women are diagnosed above the age of 50, with
almost half of the men and 45% of the women being
70 years or older [18].
Clinical trials are often skewed towards younger and
healthier populations compared to the disease popula-
tion [19], making evidence used in clinical decision
weaker. Patients in clinical trials have been shown to be
almost 10 years younger than the corresponding Medi-
care cohort [20]. In the same study, it was demonstrated
that studies tend to overestimate survival for older
Medicare patients. A systematic review from Zulman et
al. shows that one of five trials excludes patients over a
certain age, and that almost half of the remaining trials
use criteria that disproportionally can exclude older
adults [21]. It also found that just one in six trials differ-
entiates benefit by age.
Guidelines for screening use age cut-offs when recom-
mending start and cessation. These are based on estimates
of risk, benefit and harm, all of which are influenced by
age [22, 23]. Age can also affect the individual patient or
physician's decision to screen. Younger women are more
likely to be screened for breast or cervical cancer com-
pared to older women [24, 25], and general practitioners’
tendency to screen for prostate cancer using PSA-tests in-
crease with increasing patient age [26].
Several treatment guidelines use age in their recom-
mendations. Some use age when recommending treat-
ment type and length, like the new ESMO guideline on
treatment of metastatic non-small cell lung cancer which
explicitly emphasizes the age of 70 [27]. The ESMO
guideline for treatment of acute lymphoblastic leukemia
uses age-adapted treatment protocols in their treatment
recommendations [28]. Age can also be listed as one
relevant factor for deciding treatment [29], and it can be
used as guidance when referring patients to further diag-
nostics when suspicious of cancer disease [30]. NICE
uses age as an explicit cut off when deciding the cost-
effectiveness of genetic testing for individuals with a
family history of breast cancer [31].
Patient
Seventy-one relevant articles associate patient age with rele-
vant patient factors in clinical decision making. Comorbid-
ity, physiology, tumor biology and patient receptivity for
information and communication are all associated with
patient age.
A review by Pal and Hurria report that age-related de-
cline in renal blood flow and glomerular filtration rate
may affect clearance of cytotoxic agents [9]. Liver size
and blood flow decrease by age, and so does effects of
many CYP enzymes responsible for hepatic drug metab-
olism [32]. Compared to younger patients, older patients
have reduced stem cell reserve, reduced reserve of func-
tional tissue, and increased risk of comorbidity and poly-
pharmacy [33].
There is a solid link between increasing age and preva-
lence of comorbidity [34]. In a large observation of
newly diagnosed cancer patients, both severity and the
mean number of comorbidity conditions increased by
age [35]. Findings in a systematic review by Lee et al.
suggest that cancer patients with comorbidity receive
less chemotherapy and have inferior survival compared
to patients without comorbidity [36].
Age is often linked to certain cancer biology and mo-
lecular pathology patterns. In breast cancer, medullary
and inflammatory disease types are more common in
younger patients, while papillary, lobular and mucinous
types are more common in older patients [37]. Patients
under 45 years of age have almost double the proportion
of ER-/HER2- tumors and half the proportion of luminal
A tumors than patients above 65 years [38]. Similar age-
associated pathology patterns are seen in other cancer
types [39, 40].
Age can affect patient’s information processing and
participation in decision, requiring physicians to adjust
their communication and decision style. There is robust
evidence of age-related decline in deliberative functions
[41], which suggests that information given is processed
more slowly. Older patients also tend to make more im-
mediate treatment decisions, with one hypothesis being
more limited cognitive resources [42]. A recent system-
atic review suggests that physicians’ recommendation is
more influential for older patients [43]. Age is also
shown to influence information need: younger patients
below the age of 55 require more information than older
patients [44].
Intervention
We identified 215 relevant articles grouped under the
broad term interventions. More than half of the refer-
ences (125) relate patient age to treatment outcome,
while others associate age with other relevant factors like
prediction tools and quality of treatment.
The outcome of cancer is influenced by the age of the
patient, with decreasing survival for older patients [18,
39, 40, 45, 46]. For many cancer types, high age is a pre-
dictor of mortality [47–49]. However, this does not apply
exclusively for older patients: Fredholm et al. have
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shown that women with breast cancer under the age of
35 have distinctly worse survival, even with higher inten-
sity treatment [50].
Register studies show that older patients tend to re-
ceive substandard treatment: the proportion of lung can-
cer patients receiving guideline treatment declines with
increasing age [51]. Older patients with colorectal cancer
were less likely to receive the new anti-angiogenetic drug
bevacizumab [52]. Patient age is a significant predictor
of type of breast cancer surgery. Younger women receive
breast conservation surgery more often than older
women [53]. Backing this are many surveys, reporting
that physicians do take patient age into consideration
when deciding cancer treatment [54–57].
There are many different risk prediction models in use
for estimation of survival. One of the best known, Adju-
vant! Online(AO) incorporates patient age as a factor
[58]. It is shown that AO overestimates survival in both
the younger (below 40 years) and oldest (above 75 years)
age groups [59, 60]. Other prediction tools that are used
in oncology also include age, like Predict [61], for decid-
ing treatment after breast cancer surgery, and a new
model for predictions of chemotherapy toxicity, devel-
oped by Hurria et al. [62].
Discussion
This scoping review is to our knowledge the first at-
tempt to methodically map out the role of patient age in
clinical decision making in cancer care. Our findings
suggest that patient age is widely used, directly or indir-
ectly and consciously or unconsciously, to guide clinical
decisions.
Patient age is integrated into clinical decision making
in a range of ways that in sum makes it not only diffi-
cult, but almost meaningless to claim age-neutrality.
Consequentially, beliefs that physicians do and even can
make decisions completely independent of patient age
should be discarded, as such beliefs probably hinders
due consideration and discussion of the role of age.
Denying any role of age is thus unproductive and can be
harmful both for patients and for the debate. Instead, it
is time to critically appraise how much and in which
ways patient age should guide clinical decisions.
Accepting the relevance of patient age is important in
a clinical setting. A more transparent discussion will
make clinicians more attentive to their own decision
making strategy, thereby facilitating fair and consistent
decisions. The opposite, an intentional or unintentional
neglect of patient age, is likely to result in poor deci-
sions. In particular, it may lead to unjustified age-based
discrimination, in the sense that decisions based on age
are not systematically considered or justified. Acknow-
ledging the complex role of age in clinical decision mak-
ing will also benefit the academic debate. Research is
often framed as yes–no decisions on the direct influence
of age [3, 4], while our findings demonstrate a variety of
possible ways age influences clinical decisions.
Deciding when and how patient age can be justified is
a value judgement. In some cases, it is unproblematic.
Few, if any, will argue that taking into account the well-
documented association between increasing age and in-
creasing incidence of cancer is discriminatory. Nor is
anyone protesting that communication between patients
and physicians should be adapted to the patient’s age
and mental status. In these cases the use of patient age
is uncontroversial. Conversely, the poor representation
of older patients in clinical trial populations needs to be
addressed.
Often decisions about individual patients are based on
group level data, and age is typically used indirectly as a
proxy for individual patient characteristics. In modern
cancer care this practice will increasingly be replaced by
biomarkers or composite measures. Pharmacodynamic
biomarkers can inform the optimal drug dosage for a pa-
tient better then estimates based on age [63]. New can-
cer treatments will increasingly be guided by individual
tumor characteristics (see e.g. the Food and Drug Ad-
ministration’s May 2017 approval of pembrolizumab for
any solid tumors with specific genetic features [64]).
Comprehensive geriatric assessments will better estimate
older patients’ capacity and tolerance of treatment [65].
And biological age can be estimated through various al-
gorithms providing a better description of a patient’s
overall mental and physical capacity [66].
For other relationships between patient age and deci-
sion making is it more difficult to assess implications for
clinical cancer care. Is it a fact, like our review suggest,
that older patients receive less and inferior cancer treat-
ment compared to younger patients? Is this true also for
new treatments like immunotherapy? If so, is this ethic-
ally justifiable? Do oncologists think it is ethically ac-
ceptable to limit treatment based on patient age? These
questions are important in order to harness the full po-
tential of personalized medicine and require more re-
search. Both empirical and theoretical work is needed.
There are limitations to our study. We have only in-
vestigated factors guiding physician recommendations.
We acknowledge that deciding treatment is a shared de-
cision between patient and physician, but we still find it
valuable to separately investigate these factors. A scoping
review does not evaluate the quality of the studies, as
is done in systematic reviews. Nevertheless, a scoping
review can effectively help identify the many ways age
can influence decision making – not claiming that
age always affects all factors in the same way all the
time. A scoping review like this one can also serve as
a valuable basis for future in-depth research on influ-
encing factors.
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Conclusion
This article has demonstrated how patient age appears
to influence a clinical decision in a variety of ways.
While arbitrary use of age can lead to unjustified dis-
crimination, the findings suggest that is difficult, if not
impossible for a clinician to make an age-neutral deci-
sion. Acknowledging the many roles of age and being
more transparent about its use can help clinicians make
better and more ethical decisions. It can also promote a
more open and informed public debate.
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